Expands newborn screening for five rare genetic diseases

File S10260 ("Expands newborn screening for five rare genetic diseases") is before the New York Legislature and has not been decided. Latest step (May 8, 2026): In Senate Committee.

New York file S10260, before the New York Legislature. Still to be decided as of 2026-05-08.

What it does

Your newborn screened for five more genetic diseases Starting within 12 months of enactment, all babies born in New York will automatically receive blood tests for CLN2, MPS IVA, MPS VI, MPS VII, and Fabry diseases—conditions that can cause severe neurological or organ damage if caught too late.

The bigger picture

Early diagnosis enables treatment before symptoms appear Identifying these rare diseases in newborns allows doctors to start therapies (enzyme replacement, gene therapy, or supportive care) during the critical window when treatment is most effective, potentially preventing permanent disability or early death in affected children.

What to watch

Lab capacity and costs must scale within one year The state's newborn screening lab must expand testing capability and purchase new equipment within 12 months; if this timeline is too tight, implementation delays could push testing availability beyond the statutory deadline.

Official summary

Adds CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases to the newborn screening panel for New York state; requires tests be made available within twelve months.

Read the official record for S10260

See everything up for a vote · This week in New York · See what we have filed with the clerk